Celgene Corp (CELG.O)

CELG.O on Nasdaq

117.18USD
19 Dec 2014
Price Change (% chg)

$0.70 (+0.60%)
Prev Close
$116.48
Open
$117.74
Day's High
$118.73
Day's Low
$115.46
Volume
11,294,289
Avg. Vol
5,223,265
52-wk High
$119.84
52-wk Low
$66.85

CELG.O

Chart for CELG.O

About

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in... (more)

Overall

Beta: 1.09
Market Cap (Mil.): $93,592.16
Shares Outstanding (Mil.): 798.70
Dividend: --
Yield (%): --

Financials

  CELG.O Industry Sector
P/E (TTM): 61.34 37.83 38.47
EPS (TTM): 1.91 -- --
ROI: 11.99 18.99 18.25
ROE: 27.44 19.75 19.13
Search Stocks

CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, Celgene

(Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)

08 Dec 2014

Celgene profit jumps 37 percent; set to move Crohn's drug forward

- Celgene Corp on Thursday reported third-quarter profit rose 37 percent on a double-digit rise in sales of its flagship multiple myeloma drug Revlimid, and the U.S. biotechnology company expressed great confidence in a closely-watched treatment for Crohn's disease it recently acquired.

23 Oct 2014

UPDATE 2-Celgene 3rd-quarter profit jumps 37 pct, tops forecast

Oct 23 - U.S. biotechnology company Celgene Corp on Thursday reported third-quarter profit rose 37 percent on a double-digit jump in sales of its flagship multiple myeloma drug Revlimid, and raised its full-year earnings forecast.

23 Oct 2014

Celgene 3rd quarter profit up 37 percent; edges above forecast

Oct 23 - Celgene Corp on Thursday reported third quarter profit rose 37 percent on increased sales of its flagship multiple myeloma medicine Revlimid and strong demand for its other drugs, and the U.S. biotechnology company raised its full-year earnings forecast.

23 Oct 2014

Celgene's psoriasis drug gets approval for new indication

- Celgene Corp said the U.S. Food and Drugs Administration has approved the expanded use of its drug Otezla for treating patients with moderate to severe plaque psoriasis.The drug, known chemically as apremilast, is already approved for treating psoriatic arthritis, a type of arthritis associated with the skin disease.

23 Sep 2014

UPDATE 1-Celgene's psoriasis drug gets approval for new indication

Sept 23 - Celgene Corp said the U.S. Food and Drugs Administration has approved the expanded use of its drug Otezla for treating patients with moderate to severe plaque psoriasis.

23 Sep 2014

Celgene's psoriasis drug gets approval for new indication

Sept 23 - Celgene Corp said U.S. health regulators have approved the expanded use of its drug Otezla for treating patients with moderate to severe plaque psoriasis.

23 Sep 2014

UK cost agency backs Celgene bone marrow drug in change of tack

LONDON - Celgene's drug Revlimid should be an option on Britain's state health service for patients with serious bone marrow disorders and a specific chromosomal abnormality, the country's cost agency said on Wednesday.

19 Aug 2014

UK cost agency backs Celgene bone marrow drug in change of tack

LONDON, Aug 20 - Celgene's drug Revlimid should be an option on Britain's state health service for patients with serious bone marrow disorders and a specific chromosomal abnormality, the country's cost agency said on Wednesday.

19 Aug 2014

Celgene profit rises but revised outlook disappoints

- Celgene Corp reported a 25 percent rise in second-quarter profit, edging out Wall Street expectations, but a raised 2014 forecast failed to excite investors and its shares fell nearly 4 percent.

24 Jul 2014

Competitors

  Price Change
Takeda Pharmaceutical Co Ltd (4502.T) ¥5,001 +73.50
Eisai Co., Ltd (4523.T) ¥4,680 +109.00
Johnson & Johnson (JNJ.N) $105.55 -1.26
Pfizer Inc. (PFE.N) $31.94 -0.03
Novartis AG (NOVN.VX) CHF93.05 +0.95
Merck & Co., Inc. (MRK.N) $59.58 +0.60
Roche Holding Ltd. (ROG.VX) CHF270.40 -18.30
Abbott Laboratories (ABT.N) $46.05 +0.28
Sanofi SA (SASY.PA) €75.38 -0.79
AstraZeneca plc (AZN.L) 4,565.00p -7.50

Earnings vs. Estimates

Search Stocks